The Alpha Stem Cell Clinic: A model for evaluating and delivering stem cell-based therapies

Stem Cells Translational Medicine

Volumn 1, Issue 1, 2012, Pages 9-14

  Trounson, Alan ^a   DeWitt, Natalie D ^a   Feigal, Ellen G ^a  

^a California Institute for Regenerative Medicine (CIRM)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LYMPHOMA; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHEMOKINE RECEPTOR CCR5 GENE; DIABETES MELLITUS; EMBRYONIC STEM CELL; EYE DISEASE; FANCONI ANEMIA; FERTILIZATION IN VITRO; FLUORESCENCE MICROSCOPY; FOOD AND DRUG ADMINISTRATION; FUNDING; GENETIC DISORDER; GLIOBLASTOMA; GOOD MANUFACTURING PRACTICE; HEALTH INSURANCE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; NEUROLOGIC DISEASE; ORGANIZATION AND MANAGEMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; RECEPTOR GENE; REGENERATIVE MEDICINE; SAFETY; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; TERTIARY HEALTH CARE; TISSUE ENGINEERING; TREATMENT OUTCOME; ANIMAL; COOPERATION; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE FACILITY; HOSPITAL MANAGEMENT; MEDICAL RESEARCH; NONBIOLOGICAL MODEL; PUBLIC RELATIONS; STEM CELL RESEARCH; UNITED STATES;

ANIMALS; BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; HEALTH CARE SECTOR; HEALTH FACILITIES; HEALTH FACILITY ADMINISTRATION; HUMANS; INTERINSTITUTIONAL RELATIONS; MODELS, ORGANIZATIONAL; REGENERATIVE MEDICINE; RESEARCH SUPPORT AS TOPIC; STEM CELL RESEARCH; UNITED STATES;

EID: 84861028932     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2011-0027     Document Type: Article

References (22)

1. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ 2007;28:469-479.
2. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8(12):959-968.
3. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011;89(2):183-188.
4. Stevens AJ, Jensen JJ, Wyller K et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364(6):535-541.
5. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 2010;6:517-520.
6. Trounson A, Baum E, Gibbons D et al. Developing a model for successful translation of stem cell therapies. Cell Stem Cell 2010;6(6):513-516.
7. Ziebe S, Devroey P. Assisted reproductive technologies are an integrated part of national strategies addressing demographic and reproductive challenges. State of ART 2007 Workshop Group. Hum Reprod Update 2008;14(6):583-592.
8. Cohen J, Trounson A, Dawson K et al. The early days of IVF outside the UK. Hum Reprod Update 2005;11(5):439-459.
9. Hendrick SS, Cobos E. Practical model for psychosocial care. J Oncol Pract 2010;6(1):34-36.
10. Holt N, Wang J, Kim K et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28(8):839-847.
11. Marbán E, Cheng K. Heart to heart: The elusive mechanism of cell therapy. Circulation 2010;121(18):1981-1984.
12. Perumbeti A, Malik P. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. ScientificWorl-Journal 2010;10:644-654.
13. Rahman SH, Maeder ML, Joung JK et al. Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther 2011;22(8):925-933.
14. Chistiakov DA. Endogenous and exogenous stem cells: a role in lung repair and use in airway tissue engineering and transplantation. J Biomed Sci. 2010;17(1):92.
15. Atala A. Tissue engineering of human bladder. Br Med Bull 2011;97:81-104.
16. Trounson A, Thaker RG, Lomax G et al. Clinical trials for stem cell therapies. BMC Med 2011;9:52.
17. Taylor PL, Barker RA, Blume KG et al. Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell 2010;7(1):43-49.
18. http://www.cirm.ca.gov/for-research-ers/researchfunding?RFA%5B%5D=548
19. Zheng J, Umikawa M, Zhang S et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell 2011;9(2):119-130.
20. Hippen KL, Merkel SC, Schirm DK et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 2011;3(83):83ra41.
21. Condomines M, Sadelain M. Tolerance induction by allogeneic hematopoietic stem cells. Cell Stem Cell 2011;9(2):87-88.
22. Feng G, Nadig SN, Bäckdahl L et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med 2011;3(83):83ra40.